FRIDAY, JUNE 22, 2018

MedImmune's influenza vaccine ships for 2013-14 season

MedIummune announced on Friday that its FluMist Quadrivalent four-strain, nasal-spray influenza vaccine has begun shipping to distributors across the United States in preparation for the 2013-14 flu season.

This is the first time MedIummune will be shipping FluMist Quadrivalent. It had previously shipped a trivalent influenza vaccine.

FluMist Quadrivalent is the only nasal-spray quadrivalent flu vaccine that is approved by the Food and Drug Administration. The vaccine is capable of protecting against four influenza strains: two types of influenza A and two types of influenza B.

"The introduction of FluMist Quadrivalent reinforces MedImmune's continued commitment to patient health and innovation within the area of infectious disease," Dr. Chris Ambrose, MedImmune's vice president of Medical & Scientific Affairs, said. "MedImmune is one of the first manufacturers to ship quadrivalent vaccine to customers. MedImmune continues to collaborate with healthcare providers, the public health community, and select retail pharmacies to deliver vaccine as early as possible to eligible children and adults."

FluMist Quadrivalent is administered by gently spraying the vaccine into the nostrils, the place where most influenzae usually enter the body. Side effects of the vaccine can include runny or stuffy nose, sore throat and a fever that could reach over 100 degrees Fahrenheit.